Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 182

1.

RNA Interference Therapy with ARC-520 Results in Prolonged HBsAg Response in Patients with Chronic Hepatitis B Infection.

Yuen MF, Schiefke I, Yoon JH, Ahn SH, Heo J, Kim JH, Chan HLY, Yoon KT, Klinker H, Manns M, Petersen J, Schluep T, Hamilton J, Given BD, Ferrari C, Lai CL, Locarnini SA, Gish RG.

Hepatology. 2019 Oct 26. doi: 10.1002/hep.31008. [Epub ahead of print]

PMID:
31654573
2.

Screening for Nonalcoholic Fatty Liver Disease in the Primary Care Clinic.

Pandyarajan V, Gish RG, Alkhouri N, Noureddin M.

Gastroenterol Hepatol (N Y). 2019 Jul;15(7):357-365.

3.

Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Other Populations and Newer Agents.

Sasadeusz J, Grigg A, Hughes PD, Lee Lim S, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K.

Clin Liver Dis. 2019 Aug;23(3):521-534. doi: 10.1016/j.cld.2019.04.012. Epub 2019 Jun 5. Review.

PMID:
31266625
4.

Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Patients with Hematological and Solid Tumor Malignancies.

Sasadeusz J, Grigg A, Hughes PD, Lim SL, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K.

Clin Liver Dis. 2019 Aug;23(3):511-519. doi: 10.1016/j.cld.2019.04.011. Epub 2019 Jun 6. Review.

PMID:
31266624
5.

Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Transplant Recipients.

Sasadeusz J, Grigg A, Hughes PD, Lee Lim S, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K.

Clin Liver Dis. 2019 Aug;23(3):493-509. doi: 10.1016/j.cld.2019.04.010. Epub 2019 Jun 6. Review.

PMID:
31266623
6.

Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Introduction and Immunology.

Sasadeusz J, Grigg A, Hughes PD, Lee Lim S, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K.

Clin Liver Dis. 2019 Aug;23(3):487-492. doi: 10.1016/j.cld.2019.04.009. Epub 2019 Jun 6. Review.

PMID:
31266622
7.

Global Perspective on Hepatitis B Virus Infections in the Era of Effective Vaccines.

Gomes C, Wong RJ, Gish RG.

Clin Liver Dis. 2019 Aug;23(3):383-399. doi: 10.1016/j.cld.2019.04.001. Epub 2019 May 23. Review.

PMID:
31266615
8.
9.

Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy.

Yurdaydin C, Abbas Z, Buti M, Cornberg M, Esteban R, Etzion O, Gane EJ, Gish RG, Glenn JS, Hamid S, Heller T, Koh C, Lampertico P, Lurie Y, Manns M, Parana R, Rizzetto M, Urban S, Wedemeyer H; Hepatitis Delta International Network (HDIN).

J Hepatol. 2019 May;70(5):1008-1015. doi: 10.1016/j.jhep.2018.12.022. Epub 2018 Dec 27. Review.

PMID:
30982526
10.

Practical strategies for pruritus management in the obeticholic acid-treated patient with PBC: proceedings from the 2018 expert panel.

Pate J, Gutierrez JA, Frenette CT, Goel A, Kumar S, Manch RA, Mena EA, Pockros PJ, Satapathy SK, Yimam KK, Gish RG.

BMJ Open Gastroenterol. 2019 Feb 1;6(1):e000256. doi: 10.1136/bmjgast-2018-000256. eCollection 2019.

11.

More Severe Deficits in Performance Status at Time of Liver Transplant is Associated With Significantly Higher Risk of Death Following Liver Transplantation.

McCabe P, Gish RG, Cheung R, Wong RJ.

J Clin Gastroenterol. 2019 Oct;53(9):e392-e399. doi: 10.1097/MCG.0000000000001187.

PMID:
30762610
13.

Identification of recombinant strains in HCV genotype 1 and 3: Is it needed?

Zarkua J, Zakalashvili M, Gish RG, Metreveli D.

Liver Int. 2018 May;38(5):958. doi: 10.1111/liv.13729. Epub 2018 Mar 25. No abstract available.

PMID:
29479791
14.

RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg.

Wooddell CI, Yuen MF, Chan HL, Gish RG, Locarnini SA, Chavez D, Ferrari C, Given BD, Hamilton J, Kanner SB, Lai CL, Lau JYN, Schluep T, Xu Z, Lanford RE, Lewis DL.

Sci Transl Med. 2017 Sep 27;9(409). pii: eaan0241. doi: 10.1126/scitranslmed.aan0241.

15.

Identification of hepatitis C virus 2k/1b intergenotypic recombinants in Georgia.

Zakalashvili M, Zarkua J, Weizenegger M, Bartel J, Raabe M, Zangurashvili L, Kankia N, Jashiashvili N, Lomidze M, Telia T, Kerashvili V, Zhamutashvili M, Abramishvili N, Hedskog C, Chodavarapu K, Brainard DM, McHutchison JG, Mo H, Svarovskaia E, Gish RG, Rtskhiladze I, Metreveli D.

Liver Int. 2018 Mar;38(3):451-457. doi: 10.1111/liv.13540. Epub 2017 Sep 2.

PMID:
28782185
16.

Significant Hepatic Fibrosis Among Treatment-Naive Chronic Hepatitis B Virus With Increased Hepatitis B Virus DNA and Normal Alanine Aminotransferase.

Wong RJ, Le A, Nguyen MT, Trinh HN, Huynh A, Ly MT, Nguyen HA, Nguyen KK, Yang J, Garcia RT, Levitt B, da Silveira E, Gish RG.

Clin Gastroenterol Hepatol. 2018 Jan;16(1):146-148. doi: 10.1016/j.cgh.2017.07.012. Epub 2017 Jul 18. No abstract available.

PMID:
28733260
17.

Drugs in Development for Hepatitis B.

Dawood A, Abdul Basit S, Jayaraj M, Gish RG.

Drugs. 2017 Aug;77(12):1263-1280. doi: 10.1007/s40265-017-0769-2. Review.

18.

HBV/HCV Coinfection and Possible Reactivation of HBV Following DAA Use.

Gish RG.

Gastroenterol Hepatol (N Y). 2017 May;13(5):292-295. No abstract available.

19.

Hepatitis B surface antigen loss and sustained viral suppression in Asian chronic hepatitis B patients: A community-based real-world study.

Wong RJ, Nguyen MT, Trinh HN, Chan C, Huynh A, Ly MT, Nguyen HA, Nguyen KK, Torres S, Yang J, Liu B, Garcia RT, Bhuket T, Baden R, Levitt B, da Silveira E, Gish RG.

J Viral Hepat. 2017 Dec;24(12):1089-1097. doi: 10.1111/jvh.12736. Epub 2017 Jul 29.

PMID:
28581644
20.

Markov modeling in hepatitis B screening and linkage to care.

Sehr MA, Joshi KD, Fontanesi JM, Wong RJ, Bitmead RR, Gish RG.

Theor Biol Med Model. 2017 May 18;14(1):11. doi: 10.1186/s12976-017-0057-6.

21.

Management of hepatitis C virus infection in the Asia-Pacific region: an update.

Lim SG, Aghemo A, Chen PJ, Dan YY, Gane E, Gani R, Gish RG, Guan R, Jia JD, Lim K, Piratvisuth T, Shah S, Shiffman ML, Tacke F, Tan SS, Tanwandee T, Win KM, Yurdaydin C.

Lancet Gastroenterol Hepatol. 2017 Jan;2(1):52-62. doi: 10.1016/S2468-1253(16)30080-2. Epub 2016 Dec 10. Review.

PMID:
28404015
22.

Future Therapy for Hepatitis B Virus: Role of Immunomodulators.

Pham EA, Perumpail RB, Fram BJ, Glenn JS, Ahmed A, Gish RG.

Curr Hepatol Rep. 2016;15(4):237-244. Epub 2016 Nov 10. Review.

23.

Direct-acting antivirals for the treatment of chronic hepatitis C in patients with chronic kidney disease.

Kohli A, Alshati A, Georgie F, Manch R, Gish RG.

Therap Adv Gastroenterol. 2016 Nov;9(6):887-897. Epub 2016 Sep 14. Review.

24.

Safety, Tolerability, and Pharmacokinetics of ARC-520 Injection, an RNA Interference-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers.

Schluep T, Lickliter J, Hamilton J, Lewis DL, Lai CL, Lau JY, Locarnini SA, Gish RG, Given BD.

Clin Pharmacol Drug Dev. 2017 Jul;6(4):350-362. doi: 10.1002/cpdd.318. Epub 2016 Dec 12.

25.

Community-based real-world treatment outcomes of sofosbuvir/ledipasvir in Asians with chronic hepatitis C virus genotype 6 in the United States.

Wong RJ, Nguyen MT, Trinh HN, Huynh A, Ly MT, Nguyen HA, Nguyen KK, Yang J, Garcia RT, Levitt B, da Silveira E, Gish RG.

J Viral Hepat. 2017 Jan;24(1):17-21. doi: 10.1111/jvh.12609. Epub 2016 Sep 27.

PMID:
27677786
26.
27.

Race/ethnicity-specific disparities in cancer incidence, burden of disease, and overall survival among patients with hepatocellular carcinoma in the United States.

Ha J, Yan M, Aguilar M, Bhuket T, Tana MM, Liu B, Gish RG, Wong RJ.

Cancer. 2016 Aug 15;122(16):2512-23. doi: 10.1002/cncr.30103. Epub 2016 May 19.

28.

Hepatocellular Carcinoma: Current Questions and Future Directions.

Gish RG.

Gastroenterol Hepatol (N Y). 2015 Mar;11(3):182-5. No abstract available.

29.

Views of US Voters on Compensating Living Kidney Donors.

Peters TG, Fisher JS, Gish RG, Howard RJ.

JAMA Surg. 2016 Aug 1;151(8):710-6. doi: 10.1001/jamasurg.2016.0065.

PMID:
27007405
30.

Chronic hepatitis B virus in the Philippines.

Gish RG, Sollano JD Jr, Lapasaran A, Ong JP.

J Gastroenterol Hepatol. 2016 May;31(5):945-52. doi: 10.1111/jgh.13258. Review.

PMID:
26643262
31.

Predictors of hepatic decompensation after TACE for hepatocellular carcinoma.

Kohla MA, Abu Zeid MI, Al-Warraky M, Taha H, Gish RG.

BMJ Open Gastroenterol. 2015 Jun 23;2(1):e000032. doi: 10.1136/bmjgast-2015-000032. eCollection 2015.

32.

Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'.

Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R.

Clin Res Hepatol Gastroenterol. 2015 Oct;39(5):e57-9. doi: 10.1016/j.clinre.2015.08.001. No abstract available.

33.

Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'.

Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R.

Dig Liver Dis. 2015 Nov;47(11):924-6. doi: 10.1016/j.dld.2015.08.007. Epub 2015 Sep 26. No abstract available.

34.

Changing Nomenclature for PBC: From 'Cirrhosis' to 'Cholangitis'.

Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R.

Am J Gastroenterol. 2015 Nov;110(11):1536-8. doi: 10.1038/ajg.2015.312. Epub 2015 Sep 29. No abstract available.

35.

Changing Nomenclature for PBC: From 'Cirrhosis' to 'Cholangitis'.

Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R.

Clin Gastroenterol Hepatol. 2015 Nov;13(11):1867-9. doi: 10.1016/j.cgh.2015.08.025. Epub 2015 Sep 18. No abstract available.

PMID:
26386643
36.

Birth cohort-specific disparities in hepatocellular carcinoma stage at diagnosis, treatment, and long-term survival.

Yan M, Ha J, Aguilar M, Bhuket T, Liu B, Gish RG, Cheung R, Wong RJ.

J Hepatol. 2016 Feb;64(2):326-332. doi: 10.1016/j.jhep.2015.09.006. Epub 2015 Sep 18.

PMID:
26386160
37.

Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'.

Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R.

J Hepatol. 2015 Nov;63(5):1285-7. doi: 10.1016/j.jhep.2015.06.031. Epub 2015 Sep 15. Review. No abstract available.

38.

Changing nomenclature for PBC: from 'cirrhosis' to 'cholangitis'.

Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R.

Gastroenterology. 2015 Nov;149(6):1627-9. doi: 10.1053/j.gastro.2015.08.031. Epub 2015 Sep 15. No abstract available.

PMID:
26385706
39.

Changing nomenclature for PBC: from 'cirrhosis' to 'cholangitis'.

Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R.

Gut. 2015 Nov;64(11):1671-2. doi: 10.1136/gutjnl-2015-310593. Epub 2015 Sep 14. No abstract available.

PMID:
26374822
40.

Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'.

Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R.

Hepatology. 2015 Nov;62(5):1620-2. doi: 10.1002/hep.28140. Epub 2015 Sep 15. No abstract available.

PMID:
26372460
41.

Hepatocellular carcinoma: current questions and future directions.

Gish RG.

Clin Adv Hematol Oncol. 2015 Mar;13(3):176-9. No abstract available.

PMID:
26352425
42.

Data supporting updating estimates of the prevalence of chronic hepatitis B and C in the United States.

Gish RG, Cohen CA, Block JM, Brosgart CL, Block TM, Clary R, Le LT, Ninburg MH, Sandt L, Kowdley KV.

Hepatology. 2015 Nov;62(5):1339-41. doi: 10.1002/hep.28026. Epub 2015 Sep 29. No abstract available.

43.

Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent.

Gish RG, Yuen MF, Chan HL, Given BD, Lai CL, Locarnini SA, Lau JY, Wooddell CI, Schluep T, Lewis DL.

Antiviral Res. 2015 Sep;121:97-108. doi: 10.1016/j.antiviral.2015.06.019. Epub 2015 Jun 27. Review.

44.

Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities.

Gish RG, Given BD, Lai CL, Locarnini SA, Lau JY, Lewis DL, Schluep T.

Antiviral Res. 2015 Sep;121:47-58. doi: 10.1016/j.antiviral.2015.06.008. Epub 2015 Jun 16. Review.

PMID:
26092643
45.

Elevated alpha-fetoprotein: differential diagnosis - hepatocellular carcinoma and other disorders.

Wong RJ, Ahmed A, Gish RG.

Clin Liver Dis. 2015 May;19(2):309-23. doi: 10.1016/j.cld.2015.01.005. Epub 2015 Feb 27. Review.

PMID:
25921665
46.

Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine.

Bowden S, Locarnini S, Chang TT, Chao YC, Han KH, Gish RG, de Man RA, Yu M, Llamoso C, Tang H.

World J Gastroenterol. 2015 Apr 21;21(15):4644-51. doi: 10.3748/wjg.v21.i15.4644.

47.

The impact of pretransplant hepatic encephalopathy on survival following liver transplantation.

Wong RJ, Aguilar M, Gish RG, Cheung R, Ahmed A.

Liver Transpl. 2015 Jul;21(7):873-80. doi: 10.1002/lt.24153.

48.
49.

Medical interventions associated with HBV reactivation: Common and less common.

Reynolds JA, Manch RA, Gish RG.

Clin Liver Dis (Hoboken). 2015 Mar 27;5(2):32-34. doi: 10.1002/cld.413. eCollection 2015 Feb. No abstract available.

50.

High rate of core promoter and precore mutations in patients with chronic hepatitis B.

Baqai SF, Proudfoot J, Yi DH, Mangahas M, Gish RG.

Hepatol Int. 2015 Apr;9(2):209-17. doi: 10.1007/s12072-014-9598-5. Epub 2014 Dec 25.

Supplemental Content

Support Center